共 50 条
- [41] Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC PatientsJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S589 - S589Shi, Y.Xing, P.Han, X.Wang, S.Liu, Y.Liu, P.Li, J.Chang, L.Guan, Y.Zhang, Z.Wu, D.Yao, J.Xin, Y.
- [42] Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancerCANCER RESEARCH, 2024, 84 (09)Janni, WolfgangFriedl, ThomasRack, BrigitteFasching, Peter A.Hartkopf, AndreasTesch, HansLorenz, RalfHeinrich, GeorgBlohmer, Jens-UweFehm, TanjaMueller, VolkmarSchneeweiss, AndreasBeckmann, MatthiasRuebner, MatthiasHarbeck, NadiaPantel, KlausDustin, DerekCai, Mingyang
- [43] Ultra-sensitive ctDNA detection predicts response to immune checkpoint inhibition in advanced melanoma patientsCANCER RESEARCH, 2024, 84 (06)Gebhardt, ChristofferKeller, LauraHeidrich, IsabelKoett, JulianGeidel, GlennSmit, Daniel J.Simon, RonaldSchneider, Stefan W.Pugh, JasonAbbott, Charles W.Boyle, SeanChen, Richard O.Pantel, Klaus
- [44] Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle EastANNALS OF ONCOLOGY, 2023, 34 : S1626 - S1626Dawood, S.Jain, S. S.Lavingia, V.Aderka, D.Tahover, E.Temper, M.Goldman, A.Al Akasheh, M.Olsen, S.Hsing, S.Joshi, N.
- [45] Early detection of CRC Biomarker matched FFPE DNA and plasma cell-free DNA from CRC patients using a highly sensitive NGS panelCANCER RESEARCH, 2020, 80 (16)Chin, FranklinSundaram, VidyodhayaLam, Vinh Q.Liu, Dong
- [46] Effect of Plasma Input on the Clinical Sensitivity of a Real-Time PCR Assay for the Detection Of EGFR Mutation in Plasma ctDNA From NSCLC PatientsJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S559 - S559Gao, Y.Zhu, G.Li, Y.Jiang, F.Song, Q.
- [47] Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CRC) patients with resectable liver metastasesJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Vibat, Cecile Rose T.Melnikova, VladaMinarik, MarekBelsanova, BarboraHancock, SaegeHassaine, LatifaSamuelsz, ErrinLu, Timothy T.Erlander, Mark G.Benesova, Lucie
- [48] The Design for a Phase II, Randomized, Multicenter Study of CtDNA-Guided Treatment With Furmonertinib Combined Therapy or Furmonertinib Alone for Untreated Advanced EGFR Mutant Non-small-cell Lung Cancer Patients: The FOCUS-C StudyCLINICAL LUNG CANCER, 2024, 25 (07)Zhang, YaxiongChen, ZihongChen, GangHuang, YanYang, YunpengFang, WenfengZhang, Li
- [49] Role of detection and quantification of plasma ctDNA RAS mutations by BEAMing digital PCR in patients with locally advanced and metastatic pancreatic cancerANNALS OF ONCOLOGY, 2020, 31 : S149 - S149Gkoura, S.Kastrisiou, M.Kougioumtzi, A.Tzallas, C.Gkrepi, K.Goussia, A.Christopoulou, A.Magklara, A.Pentheroudakis, G.
- [50] Detection of IDH1 mutations in plasma cell-free circulating tumor DNA (ctDNA) from patients with cholangiocarcinomaCANCER RESEARCH, 2019, 79 (13)Aguado-Fraile, EliaChoe, SungGliser, CameliaSteelman, LoriJiang, LiewenFan, BinLe, KhaLowery, Maeve A.Pandya, SusanWu, Bin